Biosergen

Biosergen’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2025 comprises:

• Eric Strandqvist, appointed by Baltic Sea Fund (Östersjöstiftelsen)

• Anders Bladh, appointed by Ribbskottet Aktiebolag

• Anna Ljung, Chairman of the Board

Together, the Nomination Committee represents 59.08 percent of the shares in Biosergen as of September 30th, 2025.

The Nomination Committee shall submit proposals for the fiscal year January – December 2025 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

The Annual General Meeting for the fiscal year January – December 2025 will be held on May 19th, 2026.

Shareholders wishing to submit proposals to Biosergen’s Nomination Committee can do so by e-mail to info@biosergen.net by April 1st, 2026.

For additional information, please contact:

Tine Kold Olesen, CEO

Telephone: +45 3135 5707

E-mail: tine.olesen@biosergen.net

Mark Beveridge, CFO

Telephone: +46 76 805 8288

Email: mark.beveridge@biosergen.net

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).

ABOUT BIOSERGEN

Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.